Portrazza
Author: Dustin Phan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Portrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents downstream activity in parts of the EGFR pathway that are responsible for cellular proliferation, differentiation, and metastasis. The drug also has the potential to produce antibody-dependent cell-mediated cytotoxicity in cancer cells that express EGFR. Portrazza is a follow-up product to Erbitux (cetuximab; Eli Lilly/Merck KGaA), but unlike its predecessor it is a fully human MAb. Ideally, this allows Portrazza to have higher anti-tumor effects while presenting a lower risk for hypersensitivity.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Portrazza : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
9 Figure 87: Capmatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
11 Figure 89: Cemiplimab for non-small cell lung cancer – SWOT analysis
13 Figure 90: Datamonitor Healthcare’s drug assessment summary for cemiplimab in non-small cell lung cancer
LIST OF TABLES
5 Table 1: Portrazza drug profile
7 Table 2: Portrazza pivotal trial data in non-small cell lung cancer
14 Table 3: Portrazza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 4: Portrazza patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Entrectinib 
Sign up to the